GlassScriptPhysician profile
Thushan Narendra Desilva
NPI 1003824335
$233,427.83
in general payments reported to CMS, 2019-2025
50 companies · $32K in 2025
The $32K reported for 2025 was more than what 95% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45K · 2020: $15K · 2021: $20K · 2022: $54K · 2023: $20K · 2024: $47K · 2025: $32K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $63K · Food and Beverage: $21K · Consulting Fee: $13K · Travel and Lodging: $3,047 · Education: $377 · Honoraria: $30.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $62,725.37 |
| Food and Beverage | $20,773.87 |
| Consulting Fee | $12,770.50 |
| Travel and Lodging | $3,046.54 |
| Education | $376.67 |
| Honoraria | $30.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $92,278.47 | 2019-2025 | Rinvoq, Skyrizi, Botox |
| Allergan, INC. | $38,596.19 | 2019-2023 | |
| Galderma Laboratories, L.P. | $25,214.03 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Regeneron Healthcare Solutions, INC. | $23,245.80 | 2019-2025 | Dupixent, Libtayo |
| Ucb, INC. | $12,758.35 | 2019-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $8,196.50 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $5,051.43 | 2019-2025 | Siliq, Jublia, Cabtreo |
| E.R. Squibb & Sons, L.L.C. | $3,620.03 | 2022-2025 | Sotyktu |
| Dermavant Sciences, INC. | $2,848.76 | 2022-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $2,553.93 | 2019-2025 | |
| Leo Pharma INC. | $2,391.00 | 2019-2025 | Adbry, Anzupgo |
| Vyne Pharmaceuticals INC. | $2,259.51 | 2020-2021 | |
| Janssen Biotech, INC. | $2,184.65 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Lilly USA, LLC | $1,945.31 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Incyte Corporation | $1,275.88 | 2021-2025 | Opzelura |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thushan Desilva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.